Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NRXP
#4093
NRX Pharmaceuticals, Inc. Common Stock
2.520
0
USD
+0.80%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.80%
Monthly Change
+30.57%
6 month change
+41.57%
Year Change
+41.57%
Previous Close
2.500
0
Open
2.520
0
Bid
Ask
Low
2.520
0
High
2.520
0
Volume
19
Markets
US Stock Market
Healthcare
NRXP
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
Q4, 25
TTM
Key stats
Total common shares outstanding
33.07 M
—
Valuation ratios
Enterprise value
81.82 M
287.27 M
Price to earnings ratio
-2.03
-6.75
Price to sales ratio
47.35
—
Price to cash flow ratio
-4.11
-20.82
Price to book ratio
-3.64
-5.37
Enterprise value to EBITDA ratio
-5.08
—
Profitability ratios
Return on assets %
0.03
-4.73
Return on equity %
-0.02
0.92
Return on invested capital %
-63.39
-245.85
Gross margin %
58.49
—
Operating margin %
-470.3
—
EBITDA margin %
-672.84
—
Net margin %
36.72
—
Liquidity ratios
Quick ratio
—
—
Current ratio
0.31
0.94
Inventory turnover
—
—
Asset turnover
0.07
0.09
Solvency ratios
Debt to assets ratio
0
3.89
Debt to equity ratio
0
-1.01
Long term debt to total assets ratio
0
3.89
Long term debt to total equity ratio
0
-1.01
Per share metrics
Operating cash flow per share
-0.17
-0.44
EBIT per share
-0.22
-0.51
EBITDA per share
-0.31
-0.51
Total debt per share
0
0.81
Cash per share
0.36
0.71
Net current asset value per share
0.42
1.03
Tangible book value per share
-0.87
-3.5
Working capital per share
-0.92
-3.57
Book value per share
-0.74
-3.26
News
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates
NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript
NRx Pharmaceuticals receives FDA bioequivalence approval notice
NRx Pharmaceuticals receives FDA guidance on NRX-100 drug application
VTSAX vs. VTI: Which Vanguard Fund Should You Buy in 2026? - TipRanks.com
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45
NRx Pharmaceuticals appoints Joshua Brown as chief medical officer
NRx Builds Momentum From FDA Progress To Strategic Expansion - NRX Pharmaceuticals (NASDAQ:NRXP)
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26 - TipRanks.com
NRx Pharmaceuticals appoints Joseph M. Casper as chief operating officer
New Strong Sell Stocks for January 27th
H.C. Wainwright reiterates Buy rating on NRx Pharmaceuticals stock at $40